BBNX logo

Beta Bionics Inc. (BBNX)

$19.16

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BBNX

Market cap

$1.01B

EPS

-1.34

P/E ratio

--

Price to sales

7.8

Dividend yield

--

Beta

3.375238

Price on BBNX

Previous close

$19.34

Today's open

$19.38

Day's range

$18.81 - $19.54

52 week range

$8.80 - $32.71

Profile about BBNX

CEO

Sean Saint

Employees

--

Headquarters

Irvine, CA

Exchange

NASDAQ Global Market

Shares outstanding

52641863

Issue type

Common Stock

BBNX industries and sectors

Healthcare

Medical Equipment & Supplies

News on BBNX

BBNX DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

NEW YORK, Oct. 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the “Class Period”), of the important November 3, 2026 lead plaintiff deadline.

news source

GlobeNewsWire • 9 hours ago

news preview

BBNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Beta Bionics (BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

news source

Newsfile Corp • Oct 23, 2026

news preview

BBNX Investor Alert: Beta Bionics, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Leading the Securities Class Action Lawsuit

San Diego, California--(Newsfile Corp. - October 23, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump ("iLet").

news source

Newsfile Corp • Oct 23, 2026

news preview

BBNX Deadline News: Beta Bionics Investors are Notified of the Imminent November 3 Securities Fraud Class Action – Contact BFA Law if You Lost Money

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Beta Bionics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.

news source

GlobeNewsWire • Oct 23, 2026

news preview

BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action

SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class action lawsuit and upcoming November 3, 2026 lead plaintiff deadline under the Private Securities Litigation Reform Act (PSLRA). Investors who suffered substantial losses purchasing Beta Bionics stock during the Class Period between July 30, 2025 and February 24, 2026, inclusive, are encouraged to submit your losses now  to Hagens Berman to discuss their legal options.

news source

PRNewsWire • Oct 23, 2026

news preview

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , Oct. 23, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NasdaqGM: BBNX) of a class action securities lawsuit.

news source

PRNewsWire • Oct 24, 2026

news preview

Kaplan Fox Notifies Beta Bionics, Inc. (BBNX) Investors That Time Is Running Out to Lead the Securities Class Action - Deadline November 3, 2026

New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.

news source

Newsfile Corp • Oct 23, 2026

news preview

BBNX IMPORTANT DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

news source

Newsfile Corp • Oct 23, 2026

news preview

Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Act Ahead of the Lead Plaintiff Deadline on November 3, 2026

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.

news source

GlobeNewsWire • Oct 23, 2026

news preview

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Cla

news source

GlobeNewsWire • Oct 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Beta Bionics Inc.

Open an M1 investment account to buy and sell Beta Bionics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BBNX on M1